{
    "nctId": "NCT00630695",
    "briefTitle": "Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer",
    "officialTitle": "Evaluation of the Efficacity of Lanreotide LP 90 mg to Minimized the Lymphorrhea Post Axillary Lymphadenectomy in Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Lymphocele",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 148,
    "primaryOutcomeMeasure": "Quantity of lymph collected by the drain",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult patient (\\> 18 years),\n* Patient undergoing an axillary lymphadenectomy for breast cancer\n* Patient giving her agreement after being informed\n\nExclusion Criteria:\n\n* Patients that don't understand the trial\n* Type 2 diabetic patients\n* Cyclosporine treatment\n* Biliary lithiasis\n* Pregnancy or breast feeding\n* Allergic reaction to Lanr\u00e9otide or same class treatments\n* Patient included in another trial within the last 30 days",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}